Top

Published in:

01-12-2021 | SARS-CoV-2 | Letter to the Editors

COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica

Authors: Ana Maria Cabal-Herrera, Farrah J. Mateen

Excerpt

Dear Sirs, …

Genthon A, Chiarabini T, Baylac P et al (2021) Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. Leuk Lymphoma. https://doi.org/10.1080/10428194.2020.1869963CrossRefPubMed

Schüller H, Klein F, Lübbert M, Prager EP (2020) Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol. https://doi.org/10.1007/s00277-020-04318-6CrossRefPubMedPubMedCentral

Trimarchi H, Gianserra R, Lampo M et al (2020) Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J 13:739–741. https://doi.org/10.1093/ckj/sfaa166CrossRefPubMedPubMedCentral

Kulasekararaj AG, Lazana I, Large J et al (2020) Terminal complement inhibition dampens the inflammation during COVID-19. Br J Haematol. https://doi.org/10.1111/bjh.16916CrossRefPubMedPubMedCentral

Pike A, Muus P, Munir T et al (2020) COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience. Br J Haematol. https://doi.org/10.1111/bjh.17097CrossRefPubMedPubMedCentral

Araten DJ, Belmont HM, Schaefer-Cutillo J et al (2020) Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders. Am J Case Rep 21:e927418. https://doi.org/10.12659/AJCR.927418CrossRefPubMedPubMedCentral

Gralinski LE, Sheahan TP, Morrison TE et al (2018) Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. https://doi.org/10.1128/mBio.01753-18CrossRefPubMedPubMedCentral

Magro C, Mulvey JJ, Berlin D et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007CrossRefPubMedPubMedCentral

Carvelli J, Demaria O, Vély F et al (2020) Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 588:146–150. https://doi.org/10.1038/s41586-020-2600-6CrossRefPubMedPubMedCentral

10.

Rezaei SJ, Vogel AC, Gazdag B et al (2020) Neuromyelitis optica practice and prescribing changes in the setting of COVID-19: a survey of neurologists. J Neuroimmunol 346:577320. https://doi.org/10.1016/j.jneuroim.2020.577320CrossRefPubMedPubMedCentral

11.

Hamdy SM, Abdel-Naseer M, Shehata HS et al (2020) Management strategies of patients with neuromyelitis optica spectrum disorder during the COVID-19 pandemic era. Ther Clin Risk Manag 16:759–767. https://doi.org/10.2147/TCRM.S261753CrossRefPubMedPubMedCentral

12.

Zrzavy T, Wimmer I, Rommer PS, Berger T (2020) Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol. https://doi.org/10.1111/ene.14578CrossRefPubMedPubMedCentral

Title: COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
Authors: Ana Maria Cabal-Herrera
Farrah J. Mateen
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: SARS-CoV-2
Neuromyelitis Optica Spectrum Disease
COVID-19
Published in: Journal of Neurology / Issue 12/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10578-7